The potential role of oral fluid in antidoping testing

Clinical Chemistry

Volumn 60, Issue 2, 2014, Pages 307-322

  Anizan, Sebastien ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANABOLIC AGENT; ANTIANEMIC AGENT; ANTIESTROGEN; AROMATASE INHIBITOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CENTRAL STIMULANT AGENT; DIURETIC AGENT; GLUCOCORTICOID; GROWTH FACTOR; HUMAN GROWTH HORMONE; INSULIN; NARCOTIC AGENT; PEPTIDE HORMONE; PLASMA SUBSTITUTE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; PERFORMANCE ENHANCING SUBSTANCE;

ANTIDOPING TESTING; BLOOD ANALYSIS; COMPETITION; DOPING; DRUG ABSORPTION; DRUG MISUSE; DRUG SCREENING; DRUG STABILITY; DRUG USE; HUMAN; LIQUID; MASS FRAGMENTOGRAPHY; ORAL FLUID; REVIEW; SPORT; URINALYSIS; BLOOD; CHEMISTRY; LIMIT OF DETECTION; PROCEDURES; SALIVA; SUBSTANCE ABUSE; URINE;

DOPING IN SPORTS; HUMANS; LIMIT OF DETECTION; PERFORMANCE-ENHANCING SUBSTANCES; SALIVA; SUBSTANCE ABUSE DETECTION;

EID: 84893459616     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.209676     Document Type: Review

References (78)

1. WADA Website. A brief history of anti-doping. http://www.wada-ama.org/en/ about-wada/history/ (Accessed July 2013).
2. WADA Website. World anti-doping code. http://www.wada-ama.org/Documents/ World-Anti-Doping-Program/WADP-The-Code/WADA-Anti-Doping-CODE-2009-EN.pdf (Accessed July 2013).
3. WADA Website. The 2013 prohibited list. http://www.wada-ama.org/ Documents/World-Anti-Doping-Program/WADP-Prohibited-list/2013/ WADA-Prohibited-List-2013-EN.pdf (Accessed July 2013).
4. Huestis MA, Mazzoni I, Rabin O. Cannabis in sport: anti-doping perspective. Sports Med 2011;41:949-66.
5. Sottas PE, Robinson N, Rabin O, Saugy M. The athlete biological passport. Clin Chem 2011;57:969-76.
6. Vearrier D, Curtis JA, Greenberg MI. Biological testing for drugs of abuse. EXS 2010;100:489-517.
7. Aps JK, Martens LC. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005;150:119-31.
8. Gatti R, De Palo EF. An update: salivary hormones and physical exercise. Scand J Med Sci Sports 2011;21:157-69.
9. Milman G, Schwope DM, Gorelick DA, Huestis MA. Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin Chim Acta 2012;413:765-70.
10. Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem 2012;58:748-56.
11. WADA Website. Laboratory testing figures 2011. http://www.wada-ama.org/ Documents/Resources/Testing-Figures/WADA-2011-Laboratory-Testing-Figures.pdf (Accessed July 2013).
12. Cone EJ, Kumor K, Thompson LK, Sherer M. Correlation of saliva cocaine levels with plasma levels and with pharmacologic effects after intravenous cocaine administration in human subjects. J Anal Toxicol 1988;12:200-6.
13. Jufer R, Walsh SL, Cone EJ, Sampson-Cone A. Effect of repeated cocaine administration on detection times in oral fluid and urine. J Anal Toxicol 2006;30:458-62.
14. Scheidweiler KB, Spargo EA, Kelly TL, Cone EJ, Barnes AJ, Huestis MA. Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. Ther Drug Monit 2010;32:628-37.
15. Strano-Rossi S, Colamonici C, Botre F. Parallel analysis of stimulants in saliva and urine by gas chromatography/mass spectrometry: perspectives for "in competition" anti-doping analysis. Anal Chim Acta 2008;606:217-22.
16. Barnes AJ, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA. MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration. Ther Drug Monit 2011;33:602-8.
17. Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003;49:121-32.
18. Strano-Rossi S, Leone D, De La Torre X, Botrè F. Analysis of stimulants in oral fluid and urine by gas chromatography mass spectrometry II: pseudophedrine. J Anal Toxicol 2010;34:210-5.
19. Cone EJ. Testing human hair for drugs of abuse. I. Individual dose and time profiles of morphine and codeine in plasma, saliva, urine, and beard compared to drug-induced effects on pupils and behavior. J Anal Toxicol 1990;14:1-7.
20. Wang WL, Darwin WD, Cone EJ. Simultaneous assay of cocaine, heroin and metabolites in hair, plasma, saliva and urine by gas chromatographymass spectrometry. J Chromatogr B Biomed Appl 1994;660:279-90.
21. Jenkins AJ, Oyler JM, Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol 1995;19:359-74.
22. Saugy M, Avois L, Saudan C, Robinson N, Giroud C, Mangin P, Dvorak J. Cannabis and sport. Br J Sports Med 2006;40(Suppl 1):i13-5.
23. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995;19:443-9.
24. Milman G, Barnes AJ, Lowe RH, Huestis MA. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A 2010;1217:1513-21.
25. Milman G, Barnes A, Schwope D, Schwilke E, Goodwin R, Kelly D, et al. Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. Anal Bioanal Chem 2011;401:599-607.
26. Milman G, Barnes AJ, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, et al. Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem 2010;56:1261-9.
27. Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA. Oral fluid cannabinoids in chronic, daily cannabis smokers during sustained, monitored abstinence. Clin Chem 2011;57:1127-36.
28. Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend 2013;130:68-76.
29. Moore C, Coulter C, Uges D, Tuyay J, Van Der Linde S, Van Leeuwen A, et al. Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci Int 2011;212:227-30.
30. Kneisel S, Speck M, Moosmann B, Corneillie TM, Butlin NG, Auwarter V. LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal Bioanal Chem 2013.
31. Di Luigi L, Baldari C, Gallotta MC, Perroni F, Romanelli F, Lenzi A, Guidetti L. Salivary steroids at rest and after a training load in young male athletes: relationship with chronological age and pubertal development. Int J Sports Med 2006;27:709-17.
32. Deventer K, Mikulcikova P, Van Hoecke H, Van Eenoo P, Delbeke FT. Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry. J Pharm Biomed Anal 2006;42:474-9.
33. Van Renterghem P, Van Eenoo P, Geyer H, Schanzer W, Delbeke FT. Reference ranges for urinary concentrations and ratios of endogenous steroids, which can be used as markers for steroid misuse, in a Caucasian population of athletes. Steroids 2010;75:154-63.
34. Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am 2010;39:59-73, viii-ix.
35. Polet M, Van Gansbeke W, Deventer K, Van Eenoo P. Development of a sensitive GC-C-IRMS method for the analysis of androgens. Biomed Chromatogr 2013;27:259-66.
36. Schurmeyer T, Wickings EJ, Freischem CW, Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 1983;102:456-62.
37. Wood P. Salivary steroid assays: research or routine? Ann Clin Biochem 2009;46(Pt 3):183-96.
38. Beaven CM, Gill ND, Cook CJ. Salivary testosterone and cortisol responses in professional rugby players after 4 resistance exercise protocols. J Strength Cond Res 2008;22:426-32.
39. Schönfelder M, Hofmann H, Anielski P, Thieme D, Oberhoffer R, Michna H. Gene expression profiling in human whole blood samples after controlled testosterone application and exercise. Drug Test Anal 2011;3:652-60.
40. Slawson MH, Nielsen SM, Rollins DE, Wilkins DG. Analysis of endogenous steroids in oral fluid using gas chromatography-tandem mass spectrometry. Paper presented at: SOFT 2010 Annual Meeting, October 18-22; Richmond, VA.
41. Van Renterghem P, Van Eenoo P, Van Thuyne W, Geyer H, Schanzer W, Delbeke FT. Validation of an extended method for the detection of the misuse of endogenous steroids in sports, including new hydroxylated metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2008;876:225-35.
42. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009;94:907-13.
43. Cardoso CR, Marques M A S, Talhas IB, Caminha RC, Aquino Neto FR. Determination of oxymetholone in human plasma and saliva by high resolution gas chromatography-mass spectrometry. http://doping-info.de/proceedings/proceedings- 10-pdf/10-217.pdf (Accessed September 2013).
44. Sipoli Marques MA, Gualberto Pereira HM, De Oliveira MC, Talhas IB, Aquino Neto FR. Validation of the determination of tibolone in human urine and saliva using GC-MS for doping control and clinical studies. http://doping-info. de/proceedings/proceedings-12-pdf/12-403.pdf (Accessed September 2013).
45. Sobolevsky T, Rodchenkov G. Mass spectrometric description of novel oxymetholone and desoxymethyltestosterone metabolites identified in human urine and their importance for doping control. Drug Test Anal 2012;4:682-91.
46. Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106-12.
47. Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res 2008;7:1994-2006.
48. Groschl M. Current status of salivary hormone analysis. Clin Chem 2008;54:1759-69.
49. Lasne F, Martin L, Martin JA, De Ceaurriz J. Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 2009;94:888-90.
50. Hung GY, Jeng MJ, Lin CY, Soong WJ, Hwang B. The relationship between serum and saliva erythropoietin concentrations in adults, full-term and premature infants. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1998;39:380-5.
51. Bidlingmaier M. New detection methods of growth hormone and growth factors. Endocr Dev 2012;23:52-9.
52. Rantonen PJ, Penttila I, Meurman JH, Savolainen K, Narvanen S, Helenius T. Growth hormone and cortisol in serum and saliva. Acta Odontol Scand 2000;58:299-303.
53. Antonelli G, Cappellin E, Gatti R, Chiappin S, Spinella P, De Palo EF. Measurement of free IGF-I saliva levels: perspectives in the detection of GH/IGF axis in athletes. Clin Biochem 2007;40:545-50.
54. Ryan J, Mantle T, McQuaid S, Costigan DC. Salivary insulin-like growth factor-I originates from local synthesis. J Endocrinol 1992;135:85-90.
55. Fabre B, Maccallini G, Oneto A, Gonzalez D, Hirschler V, Aranda C, Berg G. Measurement of fasting salivary insulin and its relationship with serum insulin in children. Endocr Connect 2012;1:58-61.
56. Kerr M, Lee A, Wang PL, Purushotham KR, Chegini N, Yamamoto H, Humphreys-Beher MG. Detection of insulin and insulin-like growth factors I and II in saliva and potential synthesis in the salivary glands of mice. Effects of type 1 diabetes mellitus. Biochem Pharmacol 1995;49:1521-31.
57. Marchetti P, Grossi C, Giannarelli R, Masoni A, Cristofani R, Giannecchini M, Navales R. Salivary immunoreactive insulin: a new entry in clinical chemistry? Clin Chem 1988;34:1478-80.
58. Thevis M, Thomas A, Schanzer W. Doping control analysis of selected peptide hormones using LC-MS (/MS). Forensic Sci Int 2011;213:35-41.
59. Pasic J, Pickup JC. Salivary insulin in normal and type I diabetic subjects. Diabetes Care 1988;11:489-94.
60. Mareck U, Guddat S, Schwenke A, Beuck S, Geyer H, Flenker U, et al. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry. Drug Test Anal 2011;3:820-7.
61. Elers J, Pedersen L, Henninge J, Hemmersbach P, Dalhoff K, Backer V. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. Clin J Sport Med 2012;22:140-5.
62. Deventer K, Pozo OJ, Delbeke FT, Van Eenoo P. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis. Drug Test Anal 2012;4:449-54.
63. Mazzarino M, Bragano MC, De La Torre X, Molaioni F, Botre F. Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: endogenous steroids urinary profile after multiple oral doses. Steroids 2011;76:1400-6.
64. Deventer K, Delbeke FT, Roels K, Van Eenoo P. Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2002;16:529-35.
65. Hoiseth G, Yttredal B, Karinen R, Gjerde H, Morland J, Christophersen A. Ethyl glucuronide concentrations in oral fluid, blood and urine after volunteers drank 0.5 and 1.0 g/kg doses of ethanol. J Anal Toxicol 2010;34:319-24.
66. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF. Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:4007-14.
67. Garde AH, Hansen AM. Long-term stability of salivary cortisol. Scand J Clin Lab Invest 2005;65:433-6.
68. Matsui F, Koh E, Yamamoto K, Sugimoto K, Sin HS, Maeda Y, et al. Liquid chromatographytandem mass spectrometry (LC-MS/MS) assay for simultaneous measurement of salivary testosterone and cortisol in healthy men for utilization in the diagnosis of late-onset hypogonadism in males. Endocr J 2009;56:1083-93.
69. Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluidevaluation of sample collection devices. J Anal Toxicol 2008;32:393-401.
70. Lee D, Milman G, Schwope DM, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin Chem 2012;58:1101-9.
71. Lund HM, Oiestad EL, Gjerde H, Christophersen AS. Drugs of abuse in oral fluid collected by two different sample kits: stability testing and validation using ultra performance tandem mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3367-77.
72. Fucci N, De Giovanni N. Stability of methadone and its main metabolite in oral fluid. Drug Metab Lett 2008;2:125-9.
73. Thevis M, Thomas A, Pop V, Schanzer W. Ultrahigh pressure liquid chromatography-(tandem) mass spectrometry in human sports drug testing: possibilities and limitations. J Chromatogr A 2012;1292:38-50.
74. Schwope DM, Milman G, Huestis MA. Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. Clin Chem 2010;56:1007-14.
75. Reichardt EM, Baldwin D, Osselton MD. Effects of oral fluid contamination on two oral fluid testing systems. J Anal Toxicol 2013;37:246-9.
76. Wong RC, Tran M, Tung JK. Oral fluid drug tests: effects of adulterants and foodstuffs. Forensic Sci Int 2005;150:175-80.
77. Samyn N, Laloup M, De Boeck G. Bioanalytical procedures for determination of drugs of abuse in oral fluid. Anal Bioanal Chem 2007;388:1437-53.
78. Kintz P, Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit 2002;24:239-46.